Table 1 Clinical efficacies of various treatment modalities for cystoid macular oedema associated with hydroxychloroquine retinopathy reported in the literature
Reference (Year) | Treatment | No. of cases | Anatomic outcome | Visual outcome | Complications |
|---|---|---|---|---|---|
Kellner et al. (2014) | Topical dorzolamide or systemic acetazolamide (250 mg/day) | 3 | - No benefit in 2 of 3 - Of limited structural and functional benefit in 1 of 3 | Not reported | |
Bhavsar et al. (2015) | Topical dorzolamide | 1 | Central foveal thickness decreased from 289 to 258 μm (complete resolution) in one eye and from 456 to 325 in the other (partial resolution) | Not reported | Not reported |
Hong et al. (2016) | Oral acetazolamide | 1 | Complete resolution of CMO | 20/50 to 20/25 | None |
Parikh et al. (2016) | - Cessation of HCQ in 1 - Systemic immunosuppression (e.g., steroids, mycophenolate mofetil) and intravitreal triamcinolone in 1 | 2 | - Resolved after drug cessation - No response | - Not reported - 20/30 in the right eye and 20/25 in the left eye | Not reported |
Kim et al. (2018) | Topical dorzolamide | 2 | Complete resolution of CMO | 20/50 OD and 20/40 OS to 20/25 OU in one case, 20/30 OU to 20/25 OD and 20/20 OS in the other | None |